Injectable solutions produced from Quqiu Zhili Mixture Veterinary Grade API are compounded as aqueous sterile formulations in 316L stainless-steel mixing vessels with bottom-mounted magnetic agitation at 600 rpm. Water for Injection is drawn from a cold-loop system and held at conductivity below 1.3 µS/cm at 25°C. The API mixture is incorporated at 10–150 mg/mL active equivalent; dissolution is completed before pH adjustment with 0.1 M sodium citrate or citric acid to 5.5–6.5. Sodium chloride is added to 280–320 mOsmol/kg for isotonicity. Phosphate-based buffers are excluded when the composition contains divalent cations because insoluble phosphate precipitates have been observed during scale-up; disodium edetate at 0.01–0.05% w/v is introduced only after forced degradation data justify it. The solution is clarified through a 0.45 µm polyethersulfone prefilter and then passed through a 0.22 µm PVDF sterilizing-grade membrane under differential pressure below 2.0 bar. Terminal sterilization at 121°C for 15 min is permitted only for formulations that show no degradation products above 0.2%; otherwise aseptic filling follows EU GMP Annex 1 inside an ISO 14644-1 Class 5 cleanroom. Filled Type I glass vials conform to Ph. Eur. 3.2.1 and USP <660>; closure integrity is validated by dye ingress route. Sterility testing follows Ph. Eur. 2.6.1, bacterial endotoxin remains below 0.5 EU/mg by USP <85>, and subvisible particulate matter is controlled per USP <788>. Production-scale fills of 50 mL and 100 mL multidose vials require fill-volume checks at 30-min intervals to maintain net content within ±2.0%. The terminal dosage form is an injectable solution for cattle and piglets, packed in amber glass vials with bromobutyl rubber stoppers.

Why Do Water-Soluble Veterinary Powders Fail at High Humidity and Low Blender Fill Factors?

Quqiu Zhili Mixture Veterinary Grade API is dry-blended with dextrose monohydrate and anhydrous citric acid for oral water medication in poultry and swine. The powder formulation comprises API mixture 5–50 g/kg dose equivalent, dextrose monohydrate 960–985 g/kg, citric acid anhydrous 3–5 g/kg, and silicon dioxide 0.2–0.5 g/kg. Mixing is carried out in a double-cone blender at 55–65% fill volume and 12 rpm for 20 min. The API is first extended with carrier at a 10:1 ratio for 8 min, then discharged through a 800 µm cone mill at 3,000 rpm to break soft agglomerates. Relative humidity above 60% during charging causes surface moisture pickup in dextrose; the powder is therefore pre-dried to loss on drying below 2.0% by USP <731> and the blending room is held at 20–25°C and < 40% RH. Final blend uniformity is accepted when 10 sampling points give HPLC assay values from 90.0% to 110.0% of label, with RSD below 5.0%. The finished powder is packed in triplex laminated foil pouches under nitrogen with headspace oxygen below 1.0%. Siftability after packaging is checked against Ph. Eur. 2.9.12; not more than 5.0% of the product remains on a 500 µm sieve. The terminal dosage form is a water-soluble oral powder for broiler and swine drinking water, administered at 10–20 mg active/kg body weight/day according to the veterinary prescription and mixed for 24 h consumption periods.

In medicated feed premix manufacture, Quqiu Zhili Mixture Veterinary Grade API is incorporated into a carrier system at a concentration determined by the target in-feed dose and final feed intake. A 200 kg horizontal ribbon mixer with 25 rpm rotor speed is charged with ground corn meal or soybean mill run at 88.0–94.5 wt%, light mineral oil at 0.5–1.5 wt% as dust binder, and API mixture at 5,000–100,000 mg/kg. The API mixture is first geometrically diluted with granular calcium carbonate in 1:1, 1:4, and 1:10 steps because high active loading without stepwise dispersal produces assay RSD values above 10% at the mixer walls. Mixer fill is kept below 70% of gross volume; overfilling creates dead zones near the shaft and delays blend equilibrium beyond 20 min. After mixing, 10 thief samples are drawn from the batch at predetermined locations and assayed by HPLC against a validated method. Release is allowed when individual sample values are within 90.0–110.0% of label and RSD does not exceed 5.0%. The finished premix is added to complete feed at 1–10 kg/ton; final in-feed assay tolerance is maintained within ±10% of the species-specific label claim under EU Regulation 2019/4 and the current good manufacturing practice provisions of 21 CFR 225.1. Flush batches using corncob or rice hulls at 2–5% of mixer capacity are run after each production campaign to reduce carryover below 10 ppm of previous active. The terminal product is a medicated feed premix for swine, broilers, or calves, packaged in 25 kg multi-wall paper sacks with an inner polyethylene liner.

Granule Disintegration in Simulated Gastric Fluid Sets the Lower Use Level for Ruminant Oral Delivery

Granulated forms of Quqiu Zhili Mixture Veterinary Grade API are processed by top-spray fluid-bed granulation when oral administration to calves or horses requires reduced dust and controlled reconstitution. A representative pilot batch contains API mixture 10.0 wt%, lactose monohydrate 72.0 wt%, maize starch 14.0 wt%, hypromellose 3.0 wt%, and magnesium stearate 1.0 wt%. The binder solution is purified water with hypromellose dissolved at 3.0% w/w; spray rate is maintained at 35–45 g/min per 10 kg dry charge. Inlet air temperature is set at 60–70°C, with product bed temperature held at 32–38°C and outlet air at 35–45°C. Granulation endpoint is reached when Karl Fischer moisture content falls to 1.8–2.5%, because lower moisture increases friability and produces fines below 0.315 mm above 15.0%, while higher moisture produces agglomerates above 2.0 mm that fail dose uniformity. Dried granules are screened through 1.25 mm and 0.315 mm sieves; the retained middle fraction is filled into sachets of 1 g, 2 g, and 5 g. Dissolution testing in 900 mL of 0.1 M HCl at 37°C is performed with paddle speed 50 rpm; not less than 80.0% of label is released within 30 min per USP <711>. Sieve analysis follows Ph. Eur. 2.9.12. The terminal product is an oral granule in single-dose sachets for ruminant species, reconstituted or mixed with a small quantity of feed immediately before administration.

Tablets containing Quqiu Zhili Mixture Veterinary Grade API are made by direct compression after a roller-compaction step for high-dose formulations when the API mixture particle size distribution does not meet flow requirements. The pre-blend consists of API 25.0 wt%, microcrystalline cellulose 38.0 wt%, lactose monohydrate 30.5 wt%, crospovidone 4.0 wt%, colloidal silicon dioxide 0.5 wt%, and magnesium stearate 2.0 wt%. Raw materials are passed through a 0.8 mm oscillating sieve and blended in a 500 L bin blender at 12 rpm for 20 min with an intensifier bar switched off to avoid shear-induced particle coating by magnesium stearate. Lubricant is added in the final 5 min only; over-lubrication beyond 2.0 wt% or extended blending above 10 min has caused dissolution slowing in scale-up batches. Compression is performed on a 27-station rotary tablet press at 30–50 rpm, with precompression 1.5 kN and main compression force 10–14 kN. Tablet mass is 300 mg, thickness 3.2–3.6 mm, hardness 7–10 kp, and friability below 1.0% after 100 drops per USP <1216>. Content uniformity acceptance value is not more than 15.0 per USP <905>, and disintegration time does not exceed 15 min in water at 37°C per Ph. Eur. 2.9.1. A film coating of hydroxypropyl methylcellulose and PEG 8000 is applied at 3.0–4.0% weight gain; inlet air temperature is 60–70°C and pan speed 8–12 rpm. The terminal product is a scored veterinary tablet for companion animals or swine, blister-packed with PVC/PVDC base and aluminum lidding.

When Low-Shear Tumble Blending Replaces High-Shear Mixing for Hard Capsule Fill

For capsule products containing Quqiu Zhili Mixture Veterinary Grade API, the powder blend is prepared by low-shear tumble blending instead of high-shear granulation when the active content is sensitive to heat or moisture. The fill formulation contains API 30.0 wt%, lactose monohydrate 45.0 wt%, microcrystalline cellulose 21.0 wt%, croscarmellose sodium 4.0 wt%, silicon dioxide 0.5 wt%, and magnesium stearate 1.0 wt%. The blended powder is dried to loss on drying below 2.0%. Bulk density is controlled between 0.55 g/mL and 0.70 g/mL, tapped density between 0.70 g/mL and 0.85 g/mL, and angle of repose below 35°; values outside these ranges on an automatic capsule machine create fill weight variability above ±5.0%. Hard gelatin capsule shells are conditioned at 13.0–15.0% moisture so that body splitting is avoided during closing. Fill weight for size 1 capsules is 250 mg at machine speed 50–70 capsules/min. Weight uniformity is checked every 15 min against a 250 mg target with a ±5.0% individual limit. Disintegration of a batch of six capsules occurs within 15 min in 900 mL water at 37°C as specified in Ph. Eur. 2.9.1. The terminal product is a hard gelatin capsule for oral delivery to dogs or cats, packaged in 60 cc high-density polyethylene bottles with desiccant canisters.

Solution pH Windows and Preservative Efficacy Requirements for Multi-Component Oral Liquids

Quqiu Zhili Mixture Veterinary Grade API is solubilized in an aqueous vehicle for registered oral liquid dosage forms. The vehicle contains purified water, propylene glycol 15.0–25.0% v/v, and glycerol 5.0–10.0% v/v; a citrate buffer holds pH at 4.5–5.5 to limit ester hydrolysis of preservatives and maintain active solubility. Potassium sorbate at 0.10% w/v or a combination of methylparaben 0.18% w/v and propylparaben 0.02% w/v is used as preservative. Sodium metabisulfite 0.05% w/v is added only when forced degradation under 40°C/75% RH for 4 weeks demonstrates oxidative degradation; otherwise it is omitted to avoid sulfite sensitivity reactions in target species. Mixing is performed in a 316L stainless-steel jacketed vessel at 20–25°C and 500 rpm for 30 min, followed by 10 µm polypropylene depth filtration. The solution is filled into amber PET bottles under nitrogen headspace with oxygen below 1.0%. Clarity and absence of crystallization are assessed per Ph. Eur. 2.9.20; viscosity is maintained below 10 mPa·s to ensure the calibrated dosing cup delivers the intended volume. Preservative efficacy is evaluated by Ph. Eur. 5.1.3 criterion A against Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. The terminal product is a multidose oral solution or drench for sheep or cattle, with tamper-evident closure and dosing cup.